AstraZeneca, Neurimmune Sign Exclusive Commercialization Global Deal
01 März 2022 - 8:53AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Tuesday that its rare disease group Alexion
has closed an exclusive global deal and license agreement with
Neurimmune AG to commercialize NI006, an investigational antibody
in Phase 1b aimed at treating a cardiomyopathy.
The Anglo-Swedish pharma giant said that Alexion has agreed to
make an upfront payment to Neurimmune of $30 million, adding that
Neurimmune will continue to be responsible to complete the current
phase of the trial while Alexion pays certain trial costs.
"Alexion will make additional contingent milestone payments of
up to $730 million upon achievement of certain development,
regulatory and commercial milestones. It will also pay low-to-mid
teen royalties on net sales of any approved medicine resulting from
the collaboration," the FTSE 100 listed company said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
March 01, 2022 02:38 ET (07:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024